Charcot-Marie-Tooth Diagnosis: Tests, Genetic Causes and Inheritance

Many people live with symptoms for years without knowing what is actually causing them.

When clarity finally comes, it helps on multiple levels - medically and emotionally. Understanding what is happening in your body makes it much easier to deal with the condition.

Charcot-Marie-Tooth (CMT) is an inherited disorder of the peripheral nerves.

It disrupts the communication between the brain and muscles. How severe the symptoms are depends on the specific type. In my case, I was later diagnosed with CMT2A, a form where the nerve fibers themselves (the axons) are affected. [1].

A Charcot-Marie-Tooth diagnosis usually does not happen all at once. It typically involves several steps.

It often begins with changes in everyday life. You may notice changes in your walking pattern, weakness in your legs or a general loss of strength. This is usually followed by a detailed neurological examination.

Many people report that their symptoms were not taken seriously at first. This makes it even more important to consult specialists who are familiar with neuromuscular disorders. [2]

Early Signs: When to Seek Medical Advice

Typical early signs of CMT include:

• weakness or rapid fatigue in the feet and legs
• difficulty climbing stairs
• an unsteady gait or frequent tripping
• changes in foot shape
• later, problems with fine motor skills in the hands

If these symptoms persist, a neurological evaluation is recommended. This also helps rule out other causes such as circulation problems or spinal issues.

Neurological Examination

During a neurological exam, several functions are assessed:

• muscle strength and reflexes
• sensitivity to temperature, vibration and touch
• balance and walking pattern

Reduced reflexes or differences in muscle strength are common findings and may indicate nerve damage. [3]

Nerve Conduction Studies

Another important part of the diagnostic process is measuring nerve conduction velocity.

This test shows how fast electrical signals travel through the nerves.

In CMT2A, values are often only mildly reduced compared to other types, because the axons themselves are affected rather than the protective myelin sheath.

This helps doctors better classify the condition and plan further steps.

A definitive Charcot-Marie-Tooth diagnosis is usually confirmed through genetic testing.

This identifies the specific mutation responsible for the condition.

Why Genetic Testing Matters

• it determines the exact type of CMT
• it helps guide treatment decisions
• it allows family members to understand their risk
• it can enable participation in clinical studies

Charcot-Marie-Tooth is inherited, but not always in the same way.

CMT2A is typically passed on in an autosomal dominant pattern. This means that if one parent is affected, there is about a 50 percent chance that a child will inherit the condition.

Even within the same family, symptoms can vary significantly.

Other Inheritance Patterns

Less common forms include:

• autosomal recessive inheritance
• X-linked inheritance

A diagnosis does not only affect the body.

It often brings a mix of emotions - relief, uncertainty or fear. Questions like “What happens next?” or “What does this mean for my future?” are completely normal.

Genetic counseling can help put these questions into perspective.

The earlier CMT is diagnosed, the better you can respond:

• physiotherapy can help maintain strength and balance
• assistive devices can prevent deformities
• early diagnosis allows access to clinical studies

Understanding what is happening early opens up important options.

Being diagnosed with CMT2A changed my life, but it does not define it.

It helped me better understand my body and deal with it more consciously.

With knowledge, movement and an open mindset, it is possible to find a good path forward.

1. Züchner et al. (2021): Axonal Charcot-Marie-Tooth Disease (CMT2) Overview. NCBI/PMC.
2. Reilly et al. (2023): Diagnostic approach to inherited neuropathies. JNNP.
3. Pisciotta et al. (2024): Clinical variability and functional assessment in CMT2A. Neurological Sciences.
4. Saporta et al. (2025): Genetic diversity and family expression in Charcot-Marie-Tooth disease. PMC/NCBI.